In conclusion, our study provides strong evidence that SNX1 functions as a tumor suppressor in ovarian cancer by negatively regulating the CDK–Rb–E2F axis, suppressing EMT and enhancing paclitaxel sensitivity. Here, SNX1 is linked to ovarian carcinoma.